BioSpace News Archive

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in the ASGCT Annual Meeting taking place on May 16-20, 2023, in Los Angeles, USA.

Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.

Nippon Express Italia S.p.A., a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired IATA CEIV Pharma certification*, a quality certificate for pharmaceutical transport established by the International Air Transport Association, for its warehouse facility in Lainate, near Milan Malpensa Airport, effective April 3 of this year.

Scorpius BioManufacturing, a Texas-based biologics contract development and manufacturing organization, announced the appointment of Joe Payne as Vice President, Quality and Regulatory Affairs.

Royal Philips, a global leader in health technology, is showcasing end-to-end cardiology solutions through the care pathway at the annual meeting for the European Association of Percutaneous Cardiovascular Interventions to deliver better heart care for patients with greater efficiency.

AlzeCure Pharma AB a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, announced that the company arranges a Capital Markets Day on May 17 at 10:00-11:30 CET with Professor Bengt Winblad as an invited guest speaker.

Weslie Janeway joins bit.bio board.

Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, reported its financial results for the fiscal quarter ended March 31, 2023 and provided a business update.

Haemonetics Corporation announced that financial results for its fourth quarter fiscal 2023, which ended April 1, 2023, are available on its Investor Relations website.

Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, announced financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update.